Form 4: CRISPR Therapeutics CFO Reports Stock Transaction
Insider Transaction (Form 4)
Raju Prasad, Chief Financial Officer of CRISPR Therapeutics AG, reported a transaction in 750 shares of common stock on August 7, 2026.
Summary
- Bona fide gift: disposed of 750 Common Shares on August 7, 2026; holds 14,815 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Raju Prasad — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-07 | Bona fide gift | Common Shares | 750 | — | — | 14,815 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-07 | Bona fide gift (750 shares) |
Keywords
insider transaction, Form 4, CRSP, CRISPR Therapeutics AG, neutral, Raju Prasad
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.